CTIC - CTI BioPharma Corp.
| Previous Close | 0.9250 |
| Open | 0.8900 |
| Bid | 0.8500 x 1100 |
| Ask | 1.2800 x 800 |
| Day's Range | 0.8816 - 0.9400 |
| 52 Week Range | 0.6200 - 1.9300 |
| Volume | 130,581 |
| Avg. Volume | 266,529 |
| Market Cap | 69.487M |
| Beta (5Y Monthly) | 1.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6900 |
| Earnings Date | Mar 11, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.75 |
- Simply Wall St.
How Does Investing In CTI BioPharma Corp. (NASDAQ:CTIC) Impact The Volatility Of Your Portfolio?
Anyone researching CTI BioPharma Corp. (NASDAQ:CTIC) might want to consider the historical volatility of the share...
- PR Newswire
CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results
CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2019.
- PR Newswire
CTI BioPharma Announces Closing of Rights Offering
CTI BioPharma Corp. (Nasdaq: CTIC) today announced the closing of its previously announced rights offering (the "Rights Offering"). At the closing, CTI BioPharma sold and issued an aggregate of 15,698,995 shares of its common stock (the "Common Stock") and an aggregate of 4,429.2423 shares of its series X convertible preferred stock (the "Series X Preferred") pursuant to the exercise of subscription rights and Oversubscription Rights in the Rights Offering by existing holders of CTI Biopharma's Common Stock and series O convertible preferred stock. The Rights Offering was fully backstopped by certain existing stockholders of CTI BioPharma who agreed to purchase any shares of Common Stock and/or Series X Preferred offered in the Rights Offering that were not subscribed for (the "Oversubscription Rights"). CTI BioPharma raised aggregate gross proceeds of approximately $60.0 million in the Rights Offering.
- American City Business Journals
How CTI BioPharma will use its $60M rights offering
The Seattle biotech, which was out of compliance with Nasdaq in December, has regained its standing due to positive data shared at a conference Dec. 9.
- PR Newswire
CTI BioPharma Announces Commencement of Rights Offering
CTI BioPharma Corp. (Nasdaq: CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million (the "Rights Offering"). Under the terms of the Rights Offering, the holders, as of 5:00 p.m., New York time, on February 13, 2020, of CTI BioPharma's common stock (the "Common Stock") and series O convertible preferred stock (the "Series O Preferred"), are entitled to exercise their subscription rights to purchase their pro rata share (assuming full conversion of the Series O Preferred into shares of Common Stock) of the $60.0 million offering amount, as more fully described in the prospectus supplement (and accompanying prospectus), dated February 14, 2020, relating to the Rights Offering (the "Prospectus"). Each subscription right may be exercised to purchase a share of Common Stock at a subscription price equal to $1.00 per share of Common Stock or, in lieu of Common Stock, an equivalent number of shares of non-voting series X convertible preferred stock (the "Series X Preferred") at a purchase price equal to $10,000 per share of Series X Preferred. The subscription rights may be exercised at any time during the subscription period of February 14, 2020 through 5:00 p.m., New York time, on March 2, 2020.
- PR Newswire
CTI BioPharma Announces Proposed Rights Offering
CTI BioPharma Corp. (Nasdaq: CTIC) today announced its intent to raise $60 million through a fully backstopped rights offering. Under the terms of the rights offering, investors as of February 13, 2020 in CTI BioPharma's common stock and preferred stock will receive a subscription right entitling them to purchase their pro rata share of the $60 million offering amount. The rights offering will be fully backstopped by BVF Partners L.P., Stonepine Capital, L.P., OrbiMed Private Investments VI, LP and New Enterprise Associates, Inc. each of which have agreed to purchase, at a minimum, its respective as-converted pro rata share of the offering amount, plus an additional amount of securities that are not subscribed for by other purchasers in the rights offering, for a total of up to $60 million.
- Simply Wall St.
Should You Be Pleased About The CEO Pay At CTI BioPharma Corp.'s (NASDAQ:CTIC)
Adam Craig became the CEO of CTI BioPharma Corp. (NASDAQ:CTIC) in 2017. This analysis aims first to contrast CEO...
- Insider Monkey
Is CTI BioPharma Corp. (CTIC) A Good Stock To Buy ?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
- PR Newswire
CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Benefit in Myelofibrosis Patients with Severe Thrombocytopenia at the 61st American Society of Hematology Meeting
CTI BioPharma Corp. (Nasdaq: CTIC) today announced the presentation of data from the Company's pacritinib development program, including results from the PAC203 Phase 2 clinical trial, at the 61st American Society of Hematology (ASH) Annual Meeting being held December 7-10 in Orlando, Florida.
- Benzinga
The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...
- PR Newswire
CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting
SEATTLE , Nov. 6, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced four poster presentations and one oral presentation supporting the Company's pacritinib development program at ...
- PR Newswire
CTI BioPharma Reports Third Quarter 2019 Financial Results
SEATTLE , Nov. 4, 2019 /PRNewswire/ --Â CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter and nine months ended September 30, 2019 . "We advanced our pacritinib ...
- PR Newswire
CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia
SEATTLE, Oct. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that it has initiated patient enrollment in the PACIFICA pivotal Phase 3 trial of its investigational myelofibrosis treatment candidate, pacritinib. The PACIFICA trial will compare the safety and efficacy of 200 mg of pacritinib administered twice daily (BID) to Physician's Choice in 180 adult myelofibrosis patients with severe thrombocytopenia (platelet counts of less than 50,000 per microliter). "Initiation of the PACIFICA Phase 3 trial is an important step forward for the company and the pacritinib development program," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI BioPharma.
- PR Newswire
CTI BioPharma Reports Second Quarter 2019 Financial Results
SEATTLE , Aug. 1, 2019 /PRNewswire/ --Â CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter and six months ended June 30, 2019 . "We remain focused on advancing ...
- PR Newswire
CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis
SEATTLE, July 18, 2019 /PRNewswire/ --Â CTI BioPharma Corp. (CTIC) ("CTI" or "the Company") today announced the outcome of a Type B, End-of-Phase-2a meeting with the U.S. Food and Drug Administration ("FDA" or "the Agency") for the continued development of its investigational myelofibrosis treatment candidate, pacritinib. Following this meeting, CTI plans to evaluate 200 mg of pacritinib administered twice daily (BID) in 180 patients with myelofibrosis and severe thrombocytopenia.
- PR Newswire
CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20
SEATTLE , June 13, 2019 /PRNewswire/ --Â CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference ...
- PR Newswire
CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5
SEATTLE , May 29, 2019 /PRNewswire/ --Â CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies Global Healthcare Conference ...
- Associated Press
CTI BioPharma: 1Q Earnings Snapshot
The Seattle-based company said it had a loss of 19 cents per share. The biotechnology company posted revenue of $640,000 in the period. In the final minutes of trading on Thursday, the company's shares ...
- PR Newswire
CTI BioPharma Reports First Quarter 2019 Financial Results
SEATTLE , May 2, 2019 /PRNewswire/ --Â CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2019 . "Advancing our U.S. and European development ...
- PR Newswire
CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10
SEATTLE , April 3, 2019 /PRNewswire/ --Â CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 18 th Annual Needham Healthcare Conference ...
- Associated Press
CTI BioPharma: 4Q Earnings Snapshot
On a per-share basis, the Seattle-based company said it had profit of 1 cent. The biotechnology company posted revenue of $14.1 million in the period. For the year, the company reported that its loss narrowed ...
- Benzinga
The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 13) Kezar Life Sciences Inc (NASDAQ: KZR ) Down In The Dumps ...
- GlobeNewswire
Detailed Research: Economic Perspectives on Jason Industries, XBiotech, Dynatronics, Evolving, CTI BioPharma, and Charles & Colvard — What Drives Growth in Today's Competitive Landscape
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks
CTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue Estimates
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -30.00% and 20.50%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
CTI BioPharma: 3Q Earnings Snapshot
On a per-share basis, the Seattle-based company said it had a loss of 26 cents. The biotechnology company posted revenue of $723,000 in the period. The company's shares closed at $1.71. A year ago, they ...
